Funding · Commerce & Consumer Brands

TruNativ raises $30m in Series B led by OrbiMed

By Startup Enthusiast · 16 June 2026

What they do

TruNativ sells sugar substitutes, protein powders, and gut health supplements to Indian consumers

The company raised $30 million in a Series B round led by healthcare firm OrbiMed on June 16, 2026

Revenue grew from ₹37 crore to ₹130 crore as the startup targets international expansion and new product labs

TruNativ raised $30 million in a Series B funding round announced on June 16, 2026.
OrbiMed, a global healthcare investment firm, served as the lead investor for this transaction.
The capital mix included primary capital for growth and secondary share sales where early investors exited.
Early investors including 100Unicorns, Rainmatter, and Venture Catalysts completely exited their stakes.
Emami's stake was diluted from 19% to 10% during this financing event.
Dr. Sunny Sharma and Sumona Chakraborty from OrbiMed joined the board of directors.
The company reported ₹130 crore in revenue for FY26, up significantly from ₹37 crore the previous year.
TruNativ aims to reach ₹200 crore in revenue by FY27 with long-term goals of ₹800–1,000 crore.

India is identified as the diabetes and heart disease capital, driving demand for healthier alternatives.
The India protein market is estimated at $1.62 billion in 2026 with steady growth projections.
The startup landscape includes 2,672 nutrition-focused food startups, indicating a competitive but growing sector.
The company operates at breakeven while prioritizing aggressive growth over immediate profitability.

TruNativ offers products in sugar substitutes, protein, gut health, beauty wellness, and performance nutrition.
Flagship items include Everyday Sweet (monk fruit substitute) and Everyday Protein (heat-stable for cooking).
The brand also sells Pro Blend Whey, Everyday Fiber, and Advanced Collagen supplements.
It runs a B2B2C ingredient business supplying nutrition solutions via its 'Mark of Good' programme.
Monthly orders range between 7–10 lakh with a 45% repeat purchase rate.
Sales are split equally across website, quick commerce, and ecommerce channels.
The company plans to launch an innovation centre called 'The Good Lab' in Mumbai for R&D.
Distribution will expand nationwide through D2C, modern trade, pharmacy, and retail outlets.
HORECA partnerships will place supplements in hotel rooms, conferences, and restaurant menus.

Expand nationwide distribution across D2C, quick commerce, modern trade, pharmacy, and retail channels.
Scale the B2B2C ingredient business to supply more consumer brands.
Launch 'The Good Lab' innovation centre in Mumbai for research and development.
Enter international markets in Dubai and Singapore by the end of 2026.
Pursue HORECA partnerships to place products in hotels, conferences, and restaurants.

OrbiMed (lead) — Global healthcare investment firm providing capital and board representation.

Product: Clean-label nutrition products across protein, sugar alternatives, gut health and wellness
Customers: Health-conscious consumers seeking transparent, nutritionally balanced nutrition products
How it makes money: Direct-to-consumer brand selling through website and ecommerce platforms with offline expansion
What sets it apart: Transparent labeling and clean ingredients without artificial additives or proprietary blends